Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations - Université Claude Bernard Lyon 1 Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Gastroenterology Année : 2016

Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations

Man-Fung Yuen
  • Fonction : Auteur
Sang Hoon Ahn
  • Fonction : Auteur
Ding-Shinn Chen
  • Fonction : Auteur
Pei-Jer Chen
  • Fonction : Auteur
Geoffrey M. Dusheiko
  • Fonction : Auteur
Jin-Lin Hou
  • Fonction : Auteur
Willis C. Maddrey
  • Fonction : Auteur
Masashi Mizokami
  • Fonction : Auteur
Wai-Kay Seto
  • Fonction : Auteur
Ching-Lung Lai
  • Fonction : Auteur

Résumé

Chronic hepatitis B virus (HBV) infection evolves from immune-tolerance phase, through immune clearance phase to a quiescent phase or reactivation as hepatitis B e antigen-negative hepatitis. Persistent infection may result in the development of cirrhosis and hepatocellular carcinoma (HCC). Host factors including gender, age, family history, HLA-DP, and viral factors including HBV DNA, genotypes, precore mutations, pre-S deletions, and hepatitis B surface antigen (HBsAg) level are associated with the development of these complications. Risk scores for the development of HCC have been derived. Patients with persistently elevated alanine aminotransferase levels (\\textgreater30 for males; \\textgreater19 U/L for females) and HBV DNA levels \\textgreater2000 IU/mL should be treated. Patients with established cirrhosis with detectable HBV DNA should also be treated. The recommended first-line agents include pegylated interferon and 2 nucleos(t)ide analogs, entecavir and tenofovir. NAs require long-term treatment to maintain suppression of HBV DNA. They have been shown to decrease hepatic fibrosis, or reverse cirrhosis and to reduce the development of HCC. They have very low rates (0% to 1.2%) of resistance. HBsAg seroclearance, although the ideal endpoint, is only achievable in 10% to 12% of patients by multicenter trials usually studying relatively young patients. Patients on long-term treatment should be monitored for viral breakthrough that may be due to noncompliance or the development of resistance. Newer agents are under trials to enhance the rate of HBsAg seroclearance. However, even with the current NAs, long-term treatment of \\textgreater6 years can markedly reduce the covalently closed circular DNA, the viral component responsible for initiation of viral replication
Fichier non déposé

Dates et versions

hal-01796201 , version 1 (19-05-2018)

Identifiants

Citer

Man-Fung Yuen, Sang Hoon Ahn, Ding-Shinn Chen, Pei-Jer Chen, Geoffrey M. Dusheiko, et al.. Chronic Hepatitis B Virus Infection: Disease Revisit and Management Recommendations. Journal of Clinical Gastroenterology, 2016, 50 (4), pp.286-294. ⟨10.1097/MCG.0000000000000478⟩. ⟨hal-01796201⟩
89 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More